<?xml version="1.0" encoding="us-ascii"?><InstanceReport xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><Version>2.4.0.8</Version><ReportLongName>118 - Disclosure - License Agreements</ReportLongName><DisplayLabelColumn>true</DisplayLabelColumn><ShowElementNames>false</ShowElementNames><RoundingOption /><HasEmbeddedReports>false</HasEmbeddedReports><Columns><Column FlagID="0"><Id>1</Id><IsAbstractGroupTitle>false</IsAbstractGroupTitle><LabelSeparator>

</LabelSeparator><CurrencyCode /><FootnoteIndexer /><hasSegments>false</hasSegments><hasScenarios>false</hasScenarios><MCU><KeyName /><CurrencySymbol /><contextRef><ContextID>eol_PE11233---1310-Q0008_STD_181_20130630_0</ContextID><EntitySchema>http://www.sec.gov/CIK</EntitySchema><EntityValue>0001020214</EntityValue><PeriodDisplayName /><PeriodType>duration</PeriodType><PeriodStartDate>2013-01-01T00:00:00</PeriodStartDate><PeriodEndDate>2013-06-30T00:00:00</PeriodEndDate><Segments /><Scenarios /></contextRef><UPS /><CurrencyCode /><OriginalCurrencyCode /></MCU><CurrencySymbol /><Labels><Label Key="CalendarSupplement" Id="0" Label="6 Months Ended" /><Label Key="Calendar" Id="1" Label="Jun. 30, 2013" /></Labels></Column></Columns><Rows><Row FlagID="0"><Id>1</Id><IsAbstractGroupTitle>false</IsAbstractGroupTitle><LabelSeparator>

</LabelSeparator><Level>4</Level><ElementName>cers_LicenseAgreementsTextBlock</ElementName><ElementPrefix>cers_</ElementPrefix><IsBaseElement>false</IsBaseElement><BalanceType>na</BalanceType><PeriodType>duration</PeriodType><IsReportTitle>false</IsReportTitle><IsSegmentTitle>false</IsSegmentTitle><IsCalendarTitle>false</IsCalendarTitle><IsEquityPrevioslyReportedAsRow>false</IsEquityPrevioslyReportedAsRow><IsEquityAdjustmentRow>false</IsEquityAdjustmentRow><IsBeginningBalance>false</IsBeginningBalance><IsEndingBalance>false</IsEndingBalance><IsReverseSign>false</IsReverseSign><PreferredLabelRole>terseLabel</PreferredLabelRole><FootnoteIndexer /><Cells><Cell FlagID="0" ContextID="eol_PE11233---1310-Q0008_STD_181_20130630_0" UnitID=""><Id>1</Id><IsNumeric>false</IsNumeric><IsRatio>false</IsRatio><DisplayZeroAsNone>false</DisplayZeroAsNone><NumericAmount>0</NumericAmount><RoundedNumericAmount>0</RoundedNumericAmount><NonNumbericText>&lt;div&gt;
&lt;p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"&gt;&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;&lt;b&gt;Note 12. License
Agreements&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;The Company has
certain agreements with Fresenius which require the Company to pay
royalties on future INTERCEPT Blood System product sales at royalty
rates that vary by product: 10% of product sales for the platelet
system, 3% of product sales for the plasma system, 5% of product
sales for the red blood cell system, and 6.5% on sales of
illuminators. During each the three months ended June&amp;#xA0;30,
2013, and 2012, the Company made separate royalty payments to
Fresenius of $0.7 million, and payments of $1.6 million and $1.3
million during the six months ended June&amp;#xA0;30, 2013 and 2012,
respectively. At both June&amp;#xA0;30, 2013, and December&amp;#xA0;31,
2012, the Company owed Fresenius $0.8 million for
royalties.&lt;/font&gt;&lt;/p&gt;
&lt;p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px"&gt;
&lt;font style="FONT-FAMILY: Times New Roman" size="2"&gt;In December
2008, the Company extended its agreement with Fresenius to
manufacture finished INTERCEPT disposable kits for the platelet and
plasma systems through December&amp;#xA0;31, 2013. Under the amended
manufacturing and supply agreement, the Company pays Fresenius a
set price per kit, which is established annually, plus a fixed
surcharge per kit. In addition, volume driven manufacturing
overhead is to be paid or refunded if actual manufacturing volumes
are lower or higher than the estimated production volumes. The
Company made payments to Fresenius of $3.6 million and $3.9 million
relating to the manufacturing of the Company products during the
three months ended March&amp;#xA0;31, 2013, and 2012, respectively, and
$7.6 million and $7.5 million, during the six months ended
June&amp;#xA0;30, 2013 and 2012, respectively. At June&amp;#xA0;30, 2013,
and December&amp;#xA0;31, 2012, the Company owed Fresenius $4.9 million
and $6.2 million, respectively, for INTERCEPT disposable kits
manufactured. In connection with the warranty claims incurred by
the Company and remediation of those claims during the year ended
December&amp;#xA0;31, 2012 (see Note 1 in the Notes to Condensed
Consolidated Financial Statements under &amp;#x201C;Guarantee and
Indemnification Arrangements&amp;#x201D; for more detail), the Company
filed a warranty claim against Fresenius. Fresenius accepted the
warranty claim and has supplied the Company with replacement
product or credit notes. As a result, the Company recorded a
current asset of $1.8 million on its consolidated balance sheets as
of December&amp;#xA0;31, 2012 representing the full amount of the
warranty claim against Fresenius. As of June&amp;#xA0;30, 2013 the
Company no longer has a warranty claim against Fresenius and all
unsalable inventory has been returned to Fresenius.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</NonNumbericText><FootnoteIndexer /><CurrencyCode /><CurrencySymbol /><IsIndependantCurrency>false</IsIndependantCurrency><ShowCurrencySymbol>false</ShowCurrencySymbol><DisplayDateInUSFormat>false</DisplayDateInUSFormat></Cell></Cells><ElementDataType>nonnum:textBlockItemType</ElementDataType><SimpleDataType>na</SimpleDataType><ElementDefenition>License Agreements [Text Block]</ElementDefenition><ElementReferences>No definition available.</ElementReferences><IsTotalLabel>false</IsTotalLabel><UnitID>0</UnitID><Label>License Agreements</Label></Row></Rows><Footnotes /><IsEquityReport>false</IsEquityReport><ReportName>License Agreements</ReportName><MonetaryRoundingLevel>UnKnown</MonetaryRoundingLevel><SharesRoundingLevel>UnKnown</SharesRoundingLevel><PerShareRoundingLevel>UnKnown</PerShareRoundingLevel><ExchangeRateRoundingLevel>UnKnown</ExchangeRateRoundingLevel><HasCustomUnits>true</HasCustomUnits><IsEmbedReport>false</IsEmbedReport><IsMultiCurrency>false</IsMultiCurrency><ReportType>Sheet</ReportType><RoleURI>http://www.cerus.com/taxonomy/role/NotesToFinancialStatementsLicenseAgreementsTextBlock</RoleURI><NumberOfCols>1</NumberOfCols><NumberOfRows>1</NumberOfRows></InstanceReport>
